Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Computerized Thermal Imaging CIO (formerly COII) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (5770)	11/26/2000 6:41:54 PM
From: chirodoc	Read Replies (1) \| Respond to of 6039

*****WHAT DR. PARISKY THINKS OF CTI******* AS THE LEAD INVESTIGATOR AND RESEARCHER USING THE CTI SCANNER, HE HAS A GOOD IDEA OF ITS EFFECTIVENESS. "I have been part of the clinical trials from the beginning and I am very encouraged by the results I have seen," said Dr. Yuri Parisky, Director of Breast Imaging Services, USC/Norris Comprehensive Cancer Center in Los Angeles; a principal investigator for CTI's clinical trials; and a consultant to the company. "I see dozens of cases every week where a physiological view provided by computer-enhanced thermal imaging would be a great benefit. Too many times the only choice I have is to perform a biopsy. I am looking forward to the opportunity of adding this exciting new modality to my imaging options."

To: chirodoc who wrote (5770)	11/26/2000 11:34:43 PM
From: chirodoc	Read Replies (2) \| Respond to of 6039

*****THE IMPORTANT NEED FOR CTI SCANNER****** Here's why that's so important In 1997, more than 1.2 million women were told that their mammograms would require invasive breast biopsy to rule out malignancy. 800,000 of those biopsies were negative. Breast biopsy is painful and disfiguring. Surgical biopsy leaves scars that can mask lesions in future mammograms, making it more difficult for physicians to spot suspicious growths. The weeks between mammogram results and biopsy reports are filled with fear and anxiety for women and their families. Breast biopsies cost the healthcare system $1.6 billion each year. Reducing the number of benign biopsies may motivate more women to seek mammograms, improving their chances of finding malignancies at an earlier and more treatable stage.